

PanAmFarma

Distribuidora Farmacéutico Pan Americana SA de CV

SPECIALTY PHARMACEUTICALS | BIOSIMILARS | ONCOLOGY | VACCINES | LATIN AMERICA

Company Profile

Institutional Supply, Pharmaceutical Distribution, Manufacturing Coordination and CDMO-Linked Services

PanAmFarma is a Mexico-based pharmaceutical company focused on the sourcing, supply, distribution, manufacturing coordination and development of specialized medicines for Latin America. The company supports institutional, government, hospital and authorized B2B pharmaceutical channels with access to difficult-to-source medicines, biosimilars, oncology products, monoclonal antibodies, vaccines, plasma-related products and selected generic medicines.

Legal Name	Distribuidora Farmacéutico Pan Americana SA de CV
Commercial Name	PanAmFarma
Head Office	Avenida Paseo de la Reforma 222, Ciudad de México, CDMX 06500, Mexico
RFC / Tax ID	DFP230922B52
Pharmaceutical Licence	14-067-09-3523
UNGM Supplier No.	1084189
General Director	Dr. G. Patino Cohen
Primary Contact	Info@panamfarma.com +52 322 308 0021 +1 713 322 9272 WhatsApp: +1 409 789 9957

1. Corporate Overview

PanAmFarma operates as a specialized pharmaceutical manufacturer, laboratory-linked development partner and distributor serving Mexico and wider Latin America. The company's published corporate profile identifies its core activities as specialty pharmaceutical manufacturing, laboratory services and distribution, with a focus on regulated products that require documentation, traceability, controlled handling and qualified counterparties.

The company's commercial positioning is built around three practical pillars: regulated access to high-complexity medicines, cross-border pharmaceutical supply coordination, and development/manufacturing support for selected biosimilar, generic and complex pharmaceutical products.

Mission

To source, supply, distribute and support the manufacturing of specialized pharmaceutical products for Latin America, improving access to quality medicines while maintaining compliance with applicable regulatory, quality, customs and distribution requirements.

Operational Footprint

- Mexico corporate office in Mexico City, supporting commercial, regulatory and institutional coordination.
- United States commercial warehouse interface in Galveston, Texas, supporting international trade and logistical coordination.
- Manufacturing-linked operations India, Mexico supporting selected biosimilar and complex pharmaceuticals.
- Mexico distribution and warehousing coordination in collaboration with qualified pharmaceutical service partners.

Historical Development

The company presents a historical operating background linked to specialized medicines since 1978, followed by expansion into India-based manufacturing, international collaboration with London-based pharmaceutical channels, acquisition of Mexican distribution capabilities, and a strategic reorganization in 2022 to expand its presence across Latin America.

2. Core Business Areas

Specialty Pharmaceutical Supply	Procurement and supply coordination for difficult-to-access medicines, including oncology, biologics, vaccines, biosimilars, plasma-related therapies and selected hospital-use medicines.
B2B Distribution	Supply to authorized importers, distributors, license holders, hospitals and institutional channels, subject to applicable local permits and regulatory documentation.
CDMO-Linked Services	Formulation development, sterile fill-finish coordination, oral solid dosage manufacturing support, analytical development, validation support, packaging and labelling coordination.
Biosimilar Development	Strategic focus on biosimilars, including formulation, analytical characterization and early regulatory alignment for Latin America-focused programs.
Regulatory / Documentation Support	Quality documentation support including: CoA, GMP, MSDS/SDS, DMF/ASMF/CTD Module, CPP, Method Validation / Impurity Data and Regulatory Queries support, Quotation, Proforma & Commercial Invoice, Packing List when applicable.

3. Product and Therapeutic Focus

PanAmFarma's portfolio is positioned for institutional and professional pharmaceutical channels. Product availability, presentation, documentation and registration status are assessed case-by-case according to the molecule, destination country, buyer qualification, manufacturer release status and local import requirements.

- Monoclonal Antibodies and Biologic Therapies
- Biosimilar insulins and selected Chronic Disease Biologics
- Oncology and Chemotherapeutic Medicines
- Vaccines for Public-Health and Institutional Programs
- Plasma, Blood-Derived and Biological Products
- Specialized Biosimilars, Generic and Branded Medicines
- Selected API and formulation materials under applicable controls

Representative Product Categories

Oncology / Hematology	Examples include monoclonal antibodies, kinase inhibitors, antimetabolites and selected chemotherapy products.
Biologics / Biosimilars	Biosimilar-oriented portfolio and development work, including insulin and biologic product categories.
Vaccines	Government and institutional vaccine opportunities, subject to manufacturer availability, regulatory status and destination-country import pathway.
Hospital Use Medicines	Selected anesthetics, injectables and specialty products for qualified medical and institutional use.

4. Quality, Compliance and Logistics Approach

- B2B-only supply orientation for authorized pharmaceutical entities, institutions and licensed procurement channels.
- GDP/BPD-aligned logistics approach, including cold-chain control where required by the product specification.
- Batch-level traceability, supported by Certificate of Analysis and lot documentation when released by manufacturer or supplier.
- Commercial documentation issued according to transaction type: quotation, proforma, commercial invoice and packing list.
- Regulatory and customs coordination on buyer/importer obligations, destination-country requirements and agreed Incoterms.
- Dossier, CTD, CPP, GMP and manufacturer-controlled technical documents are treated as confidential and are released only under appropriate authorization, commercial qualification and legal/regulatory conditions.

International Order Handling

International orders are handled through a validated export process involving buyer qualification, documentation review, product availability confirmation, logistics planning and release of appropriate commercial and quality documentation. Cold-chain products are handled through controlled logistics channels when required.

5. Development and Manufacturing Capability

PanAmFarma's CDMO-linked profile includes development and manufacturing coordination for biosimilars, generics and complex pharmaceutical products. The company's published service areas include sterile fill-finish and oral solid dosage manufacturing, formulation development, environmental monitoring, calibration, validation, cGMP laboratory services, storage and distribution support.

Service Scope

- Preformulation studies and API property optimization
- Formulation development for safe, effective and stable dosage forms
- Analytical development and method validation
- Small-batch clinical trial material coordination
- API manufacturing or sourcing support, where applicable
- Sterile injectables, ophthalmic and biological product support
- Packaging, labelling and market-readiness coordination
- Scale-up and commercialization planning

Current Strategic Focus: PX-0915A

The company identifies PX-0915A as an internal biosimilar initiative focused on a widely prescribed biologic therapy for chronic disease management. The project is described as being in formulation, analytical characterization and early regulatory alignment phases, with a Latin America-focused strategy designed to support access, affordability and regional pharmaceutical capacity.

6. Suitable Engagements

Government / Public Sector	Market studies, RFQs, vaccine and specialty medicine supply discussions, public-health programs and institutional procurement support.
Hospitals / Clinics	Specialty medicine sourcing, quotation support and documentation coordination for qualified institutional buyers.
Manufacturers	Distributor appointment, regional market access, documentation-controlled product introduction and Latin America commercialization support.
Importers / Distributors	B2B supply, import pathway support, batch documentation and logistics coordination under agreed terms.
Strategic Partners	CDMO-linked development, biosimilar pipeline collaboration and regulated market-entry planning.

Contact

Distribuidora Farmacéutico Pan Americana SA de CV / PanAmFarma
Avenida Paseo de la Reforma 222, Ciudad de México, CDMX 06500, Mexico
Galveston Island, Texas, USA commercial/warehouse interface
Email: info@panamfarma.com
Tel.: +52 322 308 0021 / +1 713 322 9272
WhatsApp: +1 409 789 9957
Website: www.panamfarma.com

Professional Disclaimer

This company profile is for business, institutional and professional pharmaceutical communication only. Product availability, regulatory status, documentation release, import authorization and commercial terms are confirmed transaction by transaction. PanAmFarma does not provide medical advice and supplies regulated products only under applicable legal, regulatory and quality requirements.